Covestor’s Arbutus Biopharma ABUS Stock Holding History

Covestor’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-6,700	Closed	-$21K	–	2144
2024 Q2	$21K	Buy	+6,700	New	+$20.1K	0.01%	1174

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FCM

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Covestor's ABUS Position: Q3 2024 in Review

Covestor sold out of Arbutus Biopharma (ABUS) in Q3 2024, closing a stake of 6,700 shares — an estimated $21K sold.

Covestor first reported a position in ABUS in Q2 2024 and held it in 1 quarter. The position peaked at $21K in Q2 2024. 144 funds tracked by Wall St. Rank hold ABUS as of Q3 2024.

Covestor reported no remaining Arbutus Biopharma position as of Q3 2024 after selling out during the quarter.
Covestor sold 6,700 Arbutus Biopharma shares in Q3 2024, an estimated $21K.
Covestor first reported a position in Arbutus Biopharma in Q2 2024 and held it in 1 quarter.
Covestor's Arbutus Biopharma position peaked at $21K in Q2 2024.
144 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2024.

Based on Covestor's 13F filing for Q3 2024, filed 1 Nov 2024.